AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor antagonist. AstraZeneca licensed exclusive global rights to the molecule in 2015.
High levels of adenosine are found in tumour microenvironments and benefit the progression of cancer. By activating the adenosine A2A receptor, increased adenosine levels impair T-cell function and result in suppression of the host immune response.
AZD4635 specifically blocks adenosine signalling via the A2A receptor signalling resulting in increased immune responsiveness and potential to destroy cancer cells and decrease tumour burden, A2A receptor antagonism can therefore promote the anti-cancer response of T-cells within the tumour microenvironment, offering a novel mechanism of action as a mono- or combination therapy.
AZD4635 is currently in a Phase 1 clinical trial as a single agent and in combination with AstraZeneca's anti-PD-L1 antibody Imfinzi (durvalumab) in patients with solid malignancies.
Sosei is focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities.
The company, headquartered in Japan with R and D facilities in the UK, is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients